TOKYO -- Japan is scrambling to commercialize a treatment using induced pluripotent stem cells, hoping to mount a comeback in a field it pioneered.
Business trends
Japan hurries to regain lead in race for stem cell therapies
Australian startup closer to commercializing iPS-based treatment
An iPS cell lab at Kyoto University. These type of stem cells can be generated from adult cells, which means they are not subject to the same ethical dilemmas that come with embryonic cells. (Photo by Wataru Ito)
Read Next
Latest on Business trends
